Theodore Lee, MD
Allergy · Atlanta, GANPI 1689606881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 524 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,233, 2.4 times the $946 reported in 2019.
Across 524 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Sanofi$935
- Novartis$672
- Covis Pharma GmbH$645
- plus $5K from 31 others
What the payments were for
- Consulting fees$581%
- Food & beverage$10,76899%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,312 |
| GSK | 74 | $1,284 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $1,203 |
| Sanofi | 44 | $935 |
| Novartis | 31 | $672 |
| Covis Pharma GmbH | 36 | $645 |
| Grifols USA, LLC | 28 | $609 |
| CSL Behring | 23 | $532 |
| Amgen | 27 | $483 |
| Biocryst US Sales Co., LLC | 23 | $476 |
| Pharming Healthcare, Inc. | 21 | $465 |
| Pfizer | 11 | $268 |
| Tersera Therapeutics LLC | 10 | $256 |
| Blueprint Medicines Corporation | 9 | $248 |
| Octapharma USA, Inc. | 6 | $204 |
| Optinose US, Inc. | 9 | $169 |
| Genentech USA, Inc. | 7 | $119 |
| Shire North American Group Inc | 7 | $115 |
| Kaleo, Inc. | 5 | $90 |
| ADMA Biomanufacturing LLC | 3 | $83 |
| Alk-abello, Inc | 5 | $82 |
| Regeneron Healthcare Solutions, Inc. | 4 | $80 |
| LEO Pharma Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Azurity Pharmaceuticals, Inc. | 3 | $60 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $52 |
| Bio Products Laboratory USA, Inc. | 4 | $46 |
| Jubilant Hollisterstier LLC | 2 | $45 |
| Organon | 3 | $37 |
| Cycle Pharmaceuticals Inc | 1 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Incyte Corporation | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
| Biocryst Pharmaceuticals, Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 15 | $617,697 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $114,799 |
| Dupixent PenDupilumab | 25 | $103,929 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 22 | $86,772 |
| TezspireTezepelumab-Ekko | 20 | $81,333 |
| Dupixent SyringeDupilumab | 14 | $80,034 |
| XolairOmalizumab | 33 | $74,144 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $44,922 |
| KineretAnakinra | 15 | $42,172 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $38,159 |
| Cromolyn Sodium | 42 | $14,454 |
| AlvescoCiclesonide | 18 | $13,666 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $11,690 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $8,470 |
| Arnuity ElliptaFluticasone Furoate | 25 | $8,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $476 | $617,69715 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,284 | $167,801227 claims |
| CSL BehringHizentra | $532 | $86,77222 claims |
| AstraZenecaTezspire | $1,312 | $81,33320 claims |
| Grifols USA, LLCGamunex-C | $609 | $38,15912 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $30 | $14,45442 claims |
| Covis Pharma GmbHAlvesco | $645 | $13,66618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other allergy in Atlanta
- Amy HirshAtlanta$14K
- Carol WigginsAtlanta$5K
- Umbreen LodiAtlanta$47
- Thomas ChackoAlpharetta$63K
- Donnie DunaganAugusta$19K
- Tricia LeeDecatur$13K
- Anu MongiaCartersville$8K
- Tesneem ChaudharyAugusta$6K
- John HalwigAustell$5K
- Jaya TherattilAugusta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.